The FDA is clear­ly keep­ing up with the Kar­dashi­ans as its Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP) raised con­cerns that Khloé Kar­dashi­an’s pro­mo­tion­al video for a Bio­haven Phar­ma­ceu­ti­cals mi­graine drug made false claims about quick re­lief in as lit­tle as 15 min­utes.

In re­al­i­ty, OPDP said in its first un­ti­tled let­ter of the year, clin­i­cal work to sup­port the drug, known as Nurtec ODT, be­gan mea­sur­ing how it works two hours af­ter dos­ing.

“Claims that Nurtec ODT pro­vides re­lief in 15-30 min­utes are not sup­port­ed by the clin­i­cal tri­al da­ta,” the FDA said in its let­ter re­leased Tues­day.

The video, which orig­i­nal­ly aired on ABC’s “The View” last sum­mer, al­so claims that Nurtec ODT is more ef­fec­tive than oth­er mi­graine drugs and a “gamechang­er.”

Again, the FDA makes clear that these com­par­a­tive claims are mis­lead­ing be­cause Bio­haven has not demon­strat­ed that Nurtec ODT is clin­i­cal­ly su­pe­ri­or to or more ef­fec­tive than oth­er pre­scrip­tion and over-the-counter drugs. The com­pa­ny has 15 work­ing days to re­spond to the FDA.

“Bio­haven is work­ing close­ly with the FDA to eval­u­ate their com­ments and re­spond,” the com­pa­ny said in an SEC fil­ing on Tues­day.

This isn’t the first run-in be­tween the FDA and the Kar­dashi­ans over their pro­mo­tion of drugs. Khloé’s sis­ter Kim pro­mot­ed Duch­es­nay’s morn­ing sick­ness drug Di­clegis on In­sta­gram back in 2015 and the FDA slammed the com­pa­ny with a warn­ing let­ter for not dis­clos­ing enough risk in­for­ma­tion in the post.

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

FDA Commissioner Rob Califf joined the heads of the CDC and NIH in the hot seat today before a key House subcommittee, explaining that there needs to be a much faster, more coordinated way to oversee vaccine safety, and that foreign biopharma inspections, halted for years due to the pandemic, are slowly ramping up again.

Califf, who stressed to the House Energy and Commerce’s Subcommittee on Health that the CDC also needs better data, made clear that the FDA’s ability to monitor the safety of vaccines “would also benefit greatly by a coordinated federal public health data reporting authority.”

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.